Depomed (DEPO) Misses Q2 EPS by 1c, Trims FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Depomed Announces Second Quarter 2017 Financial Results
August 7, 2017 4:01 PM EDT- Updates Full-Year Financial Guidance -
- Second Quarter Revenues of $100 million -
- Increases Neurology Salesforce Effective September 1 -
- Conference Call Scheduled for Today at 4:30 PM EDT; Dial In Information Below -
NEWARK, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended June 30, 2017 and provided an update to the business.
Our second quarter product revenue was broadly in line with our expectations, said Arthur Higgins, President and CEO of Depomed. We... More
